MGTA 456

Drug Profile

MGTA 456

Alternative Names: Cord blood stem cell therapy - Novartis; Expanded umbilical cord blood - Novartis; HSC-835; LFU835 expanded umbilical cord blood stem cells; MGTA-456; Spanlecortemlocel

Latest Information Update: 10 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Magenta Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Haematological malignancies; Inborn error metabolic disorders
  • Clinical Phase Unknown Transplant rejection

Most Recent Events

  • 10 Apr 2018 9237546: financing info updated
  • 26 Feb 2018 Pharmacodynamics data from a preclinical study in Transplant rejection released by Magenta Therapeutics
  • 01 Jan 2018 Phase-II clinical trials in Inborn error metabolic disorders in USA (unspecified route) (NCT03406962)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top